Literature DB >> 11457387

Insights into long-range structural effects on the stereochemistry of aldol condensations: a practical total synthesis of desoxyepothilone F.

C B Lee1, Z Wu, F Zhang, M D Chappell, S J Stachel, T C Chou, Y Guan, S J Danishefsky.   

Abstract

A processable total synthesis of a potent antitumor agent, desoxyepothilone F (dEpoF, 21-hydroxy-12,13-desoxyepothilone B, 21-hydroxyepothilone D), has been accomplished. The route is highly convergent. The new technology has also been applied to a total synthesis of 12,13-desoxyepothilone (dEpoB). The crucial point of departure from previous syntheses of dEpoB and dEpoF involves presentation of the C1-C11 sector for Suzuki coupling with C3 in reduced form. Hitherto, the required S stereochemistry at C3 had been implemented via reduction of a keto function after Suzuki coupling. Whereas that chemistry worked quite well in a synthesis of dEpoB, it was not transferable to a high-yielding synthesis of dEpoF. The reduction of the keto group at C3 via a Noyori protocol after Suzuki coupling had proved to be very difficult. In our current approach, two consecutive aldol reactions are used to fashion the acyl sector. In the first aldol condensation, C6 becomes attached to C7. Following protection at C7, a two-carbon acetate equivalent is used to join C2 and C3 with very high asymmetric induction at C3. Only after this center has been implemented is the Suzuki reaction conducted. This major advance allowed us to synthesize dEpoF in a straightforward fashion. These findings found ready application in the total synthesis of dEpoB. Another part of the study involved analysis of the factors associated with aldol condensations joining C6 to C7. In the work described herein, the consequences of the status of C3 in promoting the C6-C7 aldol coupling are probed in detail. Dramatic stereochemical long-range effects uncovered during the study are described, and a working model to explain these effects has emerged.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11457387     DOI: 10.1021/ja010039j

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  11 in total

1.  The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.

Authors:  Bin Zhang; Jenna Carroll; John Q Trojanowski; Yuemang Yao; Michiyo Iba; Justin S Potuzak; Anne-Marie L Hogan; Sharon X Xie; Carlo Ballatore; Amos B Smith; Virginia M-Y Lee; Kurt R Brunden
Journal:  J Neurosci       Date:  2012-03-14       Impact factor: 6.167

2.  Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer's Disease and Related Tauopathies.

Authors:  Jane Kovalevich; Anne-Sophie Cornec; Yuemang Yao; Michael James; Alexander Crowe; Virginia M-Y Lee; John Q Trojanowski; Amos B Smith; Carlo Ballatore; Kurt R Brunden
Journal:  J Pharmacol Exp Ther       Date:  2016-03-15       Impact factor: 4.030

Review 3.  Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.

Authors:  Carlo Ballatore; Kurt R Brunden; Donna M Huryn; John Q Trojanowski; Virginia M-Y Lee; Amos B Smith
Journal:  J Med Chem       Date:  2012-09-28       Impact factor: 7.446

4.  The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies.

Authors:  Kurt R Brunden; Yuemang Yao; Justin S Potuzak; Nuria Ibarz Ferrer; Carlo Ballatore; Michael J James; Anne-Marie L Hogan; John Q Trojanowski; Amos B Smith; Virginia M-Y Lee
Journal:  Pharmacol Res       Date:  2010-12-14       Impact factor: 7.658

5.  Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.

Authors:  Kurt R Brunden; Bin Zhang; Jenna Carroll; Yuemang Yao; Justin S Potuzak; Anne-Marie L Hogan; Michiyo Iba; Michael J James; Sharon X Xie; Carlo Ballatore; Amos B Smith; Virginia M-Y Lee; John Q Trojanowski
Journal:  J Neurosci       Date:  2010-10-13       Impact factor: 6.167

6.  Total synthesis and selective activity of a new class of conformationally restrained epothilones.

Authors:  Mamoun M Alhamadsheh; Shuchi Gupta; Richard A Hudson; Lalith Perera; L M Viranga Tillekeratne
Journal:  Chemistry       Date:  2008       Impact factor: 5.236

7.  Aβ-mediated spine changes in the hippocampus are microtubule-dependent and can be reversed by a subnanomolar concentration of the microtubule-stabilizing agent epothilone D.

Authors:  Lorène Penazzi; Christian Tackenberg; Adnan Ghori; Nataliya Golovyashkina; Benedikt Niewidok; Karolin Selle; Carlo Ballatore; Amos B Smith; Lidia Bakota; Roland Brandt
Journal:  Neuropharmacology       Date:  2016-01-06       Impact factor: 5.250

8.  Altered microtubule dynamics and vesicular transport in mouse and human MeCP2-deficient astrocytes.

Authors:  Chloé Delépine; Hamid Meziane; Juliette Nectoux; Matthieu Opitz; Amos B Smith; Carlo Ballatore; Yoann Saillour; Annelise Bennaceur-Griscelli; Qiang Chang; Emily Cunningham Williams; Maxime Dahan; Aurélien Duboin; Pierre Billuart; Yann Herault; Thierry Bienvenu
Journal:  Hum Mol Genet       Date:  2015-11-24       Impact factor: 6.150

9.  Evaluating the potential of vacuolar ATPase inhibitors as anticancer agents and multigram synthesis of the potent salicylihalamide analog saliphenylhalamide.

Authors:  Sylvain Lebreton; Janis Jaunbergs; Michael G Roth; Deborah A Ferguson; Jef K De Brabander
Journal:  Bioorg Med Chem Lett       Date:  2008-07-05       Impact factor: 2.823

10.  Region-specific dendritic simplification induced by Aβ, mediated by tau via dysregulation of microtubule dynamics: a mechanistic distinct event from other neurodegenerative processes.

Authors:  Nataliya Golovyashkina; Lorène Penazzi; Carlo Ballatore; Amos B Smith; Lidia Bakota; Roland Brandt
Journal:  Mol Neurodegener       Date:  2015-11-05       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.